The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.
Atopic dermatitis
Abstract
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, with a lifetime prevalence of up to 20% and substantial effects on quality of life. AD is characterized by intense itch, recurrent eczematous lesions and a fluctuating course. AD has a strong heritability component and is closely related to and commonly co-occurs with other atopic diseases (such as asthma and allergic rhinitis). Several pathophysiological mechanisms contribute to AD aetiology and clinical manifestations. Impairment of epidermal barrier function, for example, owing to deficiency in the structural protein filaggrin, can promote inflammation and T cell infiltration. The immune response in AD is skewed towards T helper 2 cell-mediated pathways and can in turn favour epidermal barrier disruption. Other contributing factors to AD onset include dysbiosis of the skin microbiota (in particular overgrowth of Staphylococcus aureus), systemic immune responses (including immunoglobulin E (IgE)-mediated sensitization) and neuroinflammation, which is involved in itch. Current treatments for AD include topical moisturizers and anti-inflammatory agents (such as corticosteroids, calcineurin inhibitors and cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4) inhibitors), phototherapy and systemic immunosuppressants. Translational research has fostered the development of targeted small molecules and biologic therapies, especially for moderate-to-severe disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the past two decades, significant progress has been made in our understanding of the complex phenotype and mechanisms that underlie AD18, offering multiple new potential targets for pharmacological intervention19.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [18]
In the citing paper
“One of the clinical hallmarks of AD is dry, sensitive and highly permeable skin. This phenotypic characteristic is due to disturbance of epidermal barrier function (Box 1) owing to a dual mechanism1,2,18: first, a genetic origin with mutations in genes encoding functionally important structures such as filaggrin (FLG); and second, an inflammatory origin with key mediators such as IL-13 negatively”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [18]
In the citing paper
“The underlying ‘march of the adaptive immune system’ starts from antigen presentation and affects varrious pathways, ultimately offering distinct therapeutic options18,19,75–77.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [18]
In the citing paper
“T cells are recruited by locally produced chemotactic mediators, and inhibition of their migration represents an appealing strategy18,54,149,150.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [18]
In the citing paper
“Antigen-specific TH2 cells represent a numerically important component of the dermal and epidermal infiltrates in AD18.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [18]
Citations
Cites
1 retracted
RETRACTED: Skin barrier impairment at birth predicts food allergy at 2 years of age
Kelleher, M. M., Dunn-Galvin, A., Gray, C., Murray, D. M., Kiely, M., Kenny, L., McLean, W. H. I., Irvine, A. D., & Hourihane, J. O. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1312 · Cited by 169
Self-citationRetractedAsher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223
Johansson, S. G. O., Bieber, T., Dahl, R., Friedmann, P. S., Lanier, B. Q., Lockey, R. F., Motala, C., Ortega Martell, J. A., Platts-Mills, T. A. E., Ring, J., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.12.591 · Cited by 2,391
Self-citationRandomized trial of peanut consumption in infants at risk for peanut allergy
Du Toit, G., Roberts, G., Sayre, P. H., Bahnson, H. T., Radulovic, S., Santos, A. F., Brough, H. A., Phippard, D., Basting, M., Feeney, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414850 · Cited by 2,237
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationWeidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Self-citationKong, H. H., Oh, J., Deming, C., Conlan, S., Grice, E. A., Beatson, M. A., Nomicos, E., Polley, E. C., Komarow, H. D., Program, N. C. S., et al. (2012) · Genome Research · doi:10.1101/gr.131029.111 · Cited by 1,808
Hay, R. J., Johns, N. E., Williams, H. C., Bolliger, I. W., Dellavalle, R. P., Margolis, D. J., Marks, R., Naldi, L., Weinstock, M. A., Wulf, S. K., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.446 · Cited by 1,706
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421 · cited 1×
“Acute AD lesions exhibit TH2-dominant inflammation characterized by dermal infiltration of CD4(1)T cells and eosinophils with deposition of eosinophil-derived products and increased skin expression of IL-4, IL-5, and IL-13.(57) A pathogenic role for IL-4 in the setting of AD is supported by the observation that kerati…”
BackgroundSelf-citation
Research works printed but not linked: 5
- Paternoster, L. et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat. Genet. 44, 187–192 (2011). · DOI · Paper page
- Byrd, A. L. et al. Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci. Transl. Med. 9, eaal4651 (2017).
- Bath-Hextall, F. J., Jenkinson, C., Humphreys, R. & Williams, H. C. Dietary supplements for established atopic eczema. Cochrane Database Syst. Rev. 2, CD005205 (2012).
- Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S. & Finlay, A. Y. The dermatology life quality index 1994–2007: a comprehensive review of validation data and clinical results. Br. J. Dermatol. 159, 997–1035 (2008).
- Heil, P. M., Maurer, D., Klein, B., Hultsch, T. & Stingl, G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J. Dtsch. Dermatol. Ges. 8, 990–998 (2010).
Cited by
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Self-citationAtopic dermatitis endotypes and implications for targeted therapeutics
Czarnowicki, T., He, H., Krueger, J. G., & Guttman-Yassky, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.032 · Cited by 631
Pathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 635
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Self-citationGuttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00588-2 · Cited by 583
Self-citation
Metadata
- Authors
- Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D.
- Affiliations
- University Hospital Schleswig-Holstein (DE)
- University of Rochester Medicine (US)
- University of Bonn (DE)
- Kyoto University (JP)
- Trinity College Dublin (IE)
- Corresponding author
- Weidinger, Stephan
- Irvine, Alan D.
- Venue
- Nature Reviews Disease Primers
- Published
- 2018-06-21
- Volume
- 4
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4211026773
- Cited by
- 1,549
- References
- 232
- Citations by year
- 2026: 161 · 2025: 230 · 2024: 258 · 2023: 245 · 2022: 203 · 2021: 192 · 2020: 150 · 2019: 95 · 2018: 15
- FWCI
- 18.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Disease Primers (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, skin barrier dysfunction, filaggrin, Th2 immune response, Staphylococcus aureus, neuroinflammation, pruritus, corticosteroids, calcineurin inhibitors, phosphodiesterase-4 inhibitors, phototherapy, biologic therapy, atopic comorbidities, quality of life
- MeSH terms
- Filaggrin Proteins, Administration, Topical, Adrenal Cortex Hormones, Azathioprine, Boron Compounds, Chronic Disease, Dermatitis, Atopic, Humans, Immunosuppressive Agents, Intermediate Filament Proteins, Methotrexate, Quality of Life, Severity of Illness Index, Urticaria, Bridged Bicyclo Compounds, Heterocyclic, Genetic Predisposition to Disease, Phosphodiesterase 4 Inhibitors, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atopic dermatitis. https://app.cochat.ai/papers/10.1038/s41572-018-0001-z
- The paper
- Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018). Atopic dermatitis. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-018-0001-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.